Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLS PharmaceuticalsASX:BLS +1.66%46 Days Sales Outstanding is 25.19 as of Dec. 2025, which is 39% below its 10-year median of 41.06. GuruFocus rates ASX:BLS with a GF Score™ of 46/100 and a GF Value™ of A$0.71 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 836 Biotechnology companies, BLS Pharmaceuticals ranks better than 79.67% on this metric.
BLS Pharmaceuticals (ASX:BLS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
BLS Pharmaceuticals Days Sales Outstanding Related Terms
BLS Pharmaceuticals Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for BLS Pharmaceuticals's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:BLS vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, BLS Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLS Pharmaceuticals Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where BLS Pharmaceuticals's Days Sales Outstanding falls into.
BLS Pharmaceuticals Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLS Pharmaceuticals (ASX:BLS) has a Days Sales Outstanding of 25.19 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on BLS Pharmaceuticals and its competitors. This is 39% below median its historical median of 41.06. Over the past decade, BLS Pharmaceuticals' Days Sales Outstanding has ranged from 22.87 to 101.13. According to the industry distribution chart, BLS Pharmaceuticals ranks #170 out of 836 companies in the Biotechnology industry, placing it in the top 20.3%.
Is BLS Pharmaceuticals' Days Sales Outstanding too high?
BLS Pharmaceuticals' current Days Sales Outstanding of 25.19 is 39% below median its 10-year median of 41.06. Over the past 10 years, this metric has ranged from a low of 22.87 to a high of 101.13. The Biotechnology industry median Days Sales Outstanding is 68.96. BLS Pharmaceuticals' value of 25.19 is 63.5% below this industry median. Based on the distribution chart, BLS Pharmaceuticals ranks #170 out of 836 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BLS Pharmaceuticals has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #170 out of 836 companies for Days Sales Outstanding. This places BLS Pharmaceuticals in the top 20% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 68.96. BLS Pharmaceuticals' value of 25.19 is 63.5% below this benchmark. Historically, BLS Pharmaceuticals' own Days Sales Outstanding has ranged from 22.87 to 101.13 over the past decade. While the company's 10-year median is 41.06 vs. the industry median of 68.96, BLS Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.96, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLS Pharmaceuticals's current Days Sales Outstanding of 25.19 is 63.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on BLS Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLS Pharmaceuticals's current Days Sales Outstanding is 25.19, which is 39% below median its own 10-year median of 41.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (ASX:BLS) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.71, compared to a current price of A$0.92 — trading 29.6% above its estimated fair value. The current Days Sales Outstanding is 25.19, which is 39% below median its 10-year median of 41.06 and 63.5% below the Biotechnology industry median of 68.96. BLS Pharmaceuticals' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For BLS Pharmaceuticals (ASX:BLS), the current Days Sales Outstanding is 25.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (ASX:BLS) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of A$0.92 is trading 29.6% above its estimated GF Value™ of A$0.71.
GuruFocus considers BLS Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ASX:BLS:
Days Sales Outstanding: 25.19 (39% below median its 10-year median of 41.06)
GF Value™: A$0.71 vs. price of A$0.92 (29.6% above fair value)
Industry Position: 63.5% below the Biotechnology median (#170 of 836)
No single metric tells the full story. See the ASX:BLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
46GF Score
Get the complete analysis for ASX:BLS
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BLS has been successfully added to your 
